We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Rivaroxaban
MedXY News
EnglishTag

Rivaroxaban

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial
Hematology-Oncologyisolated distal DVTRecurrence Risk

Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial

By MedXY|Jul 7, 2026

This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.

Safety and Effectiveness of Rivaroxaban Thromboprophylaxis in ACTH-Dependent Cushing Syndrome
Diabetes & EndocrinologyACTH-dependent Cushing syndrome
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Rivaroxaban

Safety and Effectiveness of Rivaroxaban Thromboprophylaxis in ACTH-Dependent Cushing Syndrome

By MedXY|May 26, 2026

Routine oral rivaroxaban prophylaxis in ACTH-dependent Cushing syndrome was associated with no new VTE events after implementation and no bleeding complications, suggesting it is a safe and effective preventive strategy.

Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation
CardiologyAbelacimabatrial fibrillation

Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation

By MedXY|Mar 12, 2026

A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populat

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial
CardiologyCardiologyclinical trial

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

By MedXY|Mar 9, 2026

The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor b

VOYAGER-PAD Insight: Prior Revascularization History Mandates More Aggressive Antithrombotic Therapy
CardiologyPeripheral Artery DiseaseRevascularization

VOYAGER-PAD Insight: Prior Revascularization History Mandates More Aggressive Antithrombotic Therapy

By MedXY|Mar 2, 2026

A VOYAGER-PAD sub-analysis reveals that patients with prior limb revascularization are at significantly higher risk for adverse events but derive a greater relative benefit from low-dose rivaroxaban plus aspirin.

Low-Dose Rivaroxaban Fails to Significantly Reduce Left Ventricular Thrombosis in Anterior STEMI: Results of the APERITIF Trial
CardiologyanticoagulationCardiac Magnetic Resonance

Low-Dose Rivaroxaban Fails to Significantly Reduce Left Ventricular Thrombosis in Anterior STEMI: Results of the APERITIF Trial

By MedXY|Mar 2, 2026

The APERITIF randomized clinical trial found that adding low-dose rivaroxaban to dual antiplatelet therapy (DAPT) did not significantly reduce the incidence of left ventricular thrombus at one month in anterior STEMI patients, while signifi

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial
Cardiologyatrial fibrillationcognitive decline

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial

By MedXY|Jan 22, 2026

The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the

Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin
Cardiologyanticoagulationatrial fibrillation

Does Anticoagulation After Successful AF Ablation Matter? The OCEAN Trial Shows No Clear Advantage of Rivaroxaban over Aspirin

By MedXY|Nov 10, 2025

In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications
Gastroenterologyanticoagulationcirrhosis

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

By MedXY|Oct 28, 2025

The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications
Gastroenterologyanticoagulationcirrhosis

Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications

By MedXY|Oct 28, 2025

The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial
Clinical UpdatesAntithrombotic Therapyatrial fibrillation

Age-Stratified Outcomes of Rivaroxaban Monotherapy in Atrial Fibrillation with Stable Coronary Artery Disease: Insights from the AFIRE Trial

By MedXY|Sep 27, 2025

This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial
Cardiologyanticoagulationatrial fibrillation

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

By MedXY|Oct 9, 2025

The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.

Extended Rivaroxaban Therapy in Cancer Patients with Low-Risk Pulmonary Embolism: 6 OR 18 Months？
Oncologycancerpulmonary embolism

Extended Rivaroxaban Therapy in Cancer Patients with Low-Risk Pulmonary Embolism: 6 OR 18 Months？

By MedXY|Oct 5, 2025

An 18-month course of rivaroxaban significantly lowers recurrent venous thromboembolism compared to 6 months in cancer patients with low-risk pulmonary embolism without a substantial increase in major bleeding risk.

Evaluating Aspirin Plus Rivaroxaban versus Rivaroxaban Alone to Prevent Venous Stent Thrombosis in Post-Thrombotic Syndrome: Insights from the ARIVA Trial
CardiologyAspirinRivaroxaban

Evaluating Aspirin Plus Rivaroxaban versus Rivaroxaban Alone to Prevent Venous Stent Thrombosis in Post-Thrombotic Syndrome: Insights from the ARIVA Trial

By MedXY|Oct 3, 2025

The ARIVA trial found no superior benefit of adding aspirin to rivaroxaban over rivaroxaban alone in preventing venous stent thrombosis within 6 months post-intervention in post-thrombotic syndrome patients, with both regimens showing high

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial
CardiologyAbelacimabAntiplatelet Therapy

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

By MedXY|Oct 3, 2025

The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities